Expediting the Development of Patient-Specific iSPC Cell Therapies
Stefan Braam, PhD, chief executive officer of Ncardia and Cellistic discussed the companies’ work in the cell therapy space.
“We make induced pluripotent stem cells (iPSCs), we differentiate them to target cells, such as heart muscle cells, or neurons. We manufacture those cells at scale and work with therapeutic developers to build the most relevant human biology. We can start with a patient with heart failure, or patient with a with a neurological disease, make IPSCs that are truly patient specific and use that in drug discovery to accurately predict whether a drug is going to be safe and effective for that patient population.”
Ncardia is a a company working in contract research, development and manufacture of iPSC-based solutions for early and preclinical drug discovery, with a focus on cardiovascular and neural cells. Its goal is to enable pharmaceutical and therapeutics companies to make more confident decisions in discovery and development by integrating iPSC technologies into their screening processes. The company works with others to research, development and manufacture human induced pluripotent stem cell (iPSC)-based therapies early and preclinical drug discovery.
In April 2022, Ncardia launched Cellistic, a company focused on iPSC-based process development and manufacturing, to leverage Ncardia’s scientific and technical knowledge for cell therapy development. Cellistic is building proprietary manufacturing platforms that can deliver iPSC-based immune cells at scale.
CGTLive spoke with Stefan Braam, PhD, chief executive officer of Ncardia and Cellistic, to learn more about the companies and their work in the drug discovery and cell therapy space. He also discussed possible future avenues for cell therapy.
